Exelixis, Inc. (EXEL) announced that its supplemental new drug application (sNDA) for cabozantinib will be discussed at an Oncologic Drugs Advisory Committee (“ODAC”) meeting in March 2025.The sNDA is seeking approval for the drug to treat adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET).Exelixis’ shares have surged 48.9% year to date against the industry’s decline of 7.8%.Image Source: Zacks Investment ResearchDetails of EXEL’s sNDA f ...